Background and objective: Osteoporosis is a major comorbidity of COPD, but the mechanistic links between diseases of the lung and the bone remain elusive. Human neutrophils express the osteoclast activation factor RANKL (receptor activator of NF-kB ligand) and act directly on osteoclasts to promote bone loss. Given that neutrophils are key effector cells in the pathogenesis of COPD, these same cells, by expressing RANKL, may be involved in osteoporosis of COPD. Methods: We enrolled 59 male patients with COPD, 32 smokers with normal lung function and 25 healthy non-smokers of the same gender as controls. The expression of RANKL on peripheral neutrophils was detected by flow cytometry. The plasma concentrations of pro-inflammatory cytokines were measured by ELISA. We analysed the association of RANKL + neutrophils with bone mineral density (BMD), lung function and the levels of cytokines. Results: RANKL + neutrophils in the blood of COPD patients were increased as compared to smokers and healthy controls, and the percentage of RANKL + neutrophils was higher in patients with low BMD as compared to those with normal BMD. The percentage of RANKL
INTRODUCTION
COPD is an inflammatory disorder characterized by persistent and progressive airflow limitation with high morbidity and mortality, 1 which are attributable not only to the lung disease, but also to its multiple comorbidities, such as cardiovascular diseases, diabetes and osteoporosis. 2, 3 Osteoporosis is a major comorbidity of COPD and is associated with poor health status and prognosis. 1, 4 The mechanisms underlying bone loss in COPD are multifactorial, 5 and systemic inflammation is believed to play a central role, 6 but it remains unclear how systemic inflammation interacts with bone metabolism, and what are the culprit cells and molecules in this complex process. 7, 8 Members of the receptor activator of NF-kB (RANK), receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG) system are critical in bone homeostasis through regulation of osteoclasts. 9 RANKL, by binding to RANK on preosteoclast cells, promotes osteoclastogenesis, while OPG, the decoy receptor of RANKL, negatively regulates this process. Our previous study showed that in COPD patients with osteoporosis, the blood level of soluble RANKL and the ratio of RANKL/OPG were increased and associated inversely with bone mineral density (BMD), 10 suggesting that the disturbance of the RANKL/RANK pathway, probably by interaction with systemic inflammation, is involved in bone loss in COPD. Membrane-bound RANKL (mRANKL) was expressed by a variety of immune cells, including T lymphocytes and neutrophils. In chronic inflammation, expression of mRANKL by neutrophils was upregulated, and RANKL-expressing neutrophils can induce osteoclastogenesis by direct cell contact with osteoclasts. 11 Given that neutrophils are the predominant effector cells in airway inflammation and lung destruction, and that there is evidence of systemic activation of neutrophils in COPD, 12 we hypothesized that circulating neutrophils may have upregulated RANKL expression and participate in bone resorption in COPD.
Recent studies have shown that circulating neutrophils can be divided into three subpopulations by the expression level of CD11b, CD16 and CD62L, 13 14 Whether imbalance of neutrophil subpopulations exists in COPD and whether it is associated with the upregulated RANKL expression remain to be explored.
METHODS

Study subjects
Fifty-nine male patients with stable COPD (all current or former smokers) were recruited consecutively from October 2014 to June 2015 in the Department of Respiratory Medicine, Beijing Tongren Hospital, Capital Medical University, China. Female patients were excluded from the study to avoid the influence of postmenopausal osteoporosis. Thirty-two male smokers with normal lung function and 25 male never-smokers with normal lung function (normal controls), who were undergoing routine health check-up in this hospital, were also recruited during the same period. The baseline characteristics of the subjects are summarized in Table 1 . COPD was diagnosed based on the criteria of Global Initiative for Chronic Obstructive Lung Disease (GOLD). 1 COPD was defined by a post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) < 0.70. According to the GOLD criteria, 30 COPD patients had stage 2 (FEV1 between 80% and 50% predicted), 20 had stage 3 (FEV1 between 50% and 30% predicted) and 9 had stage 4 (FEV1 < 30% predicted) disease. The majority of the enrolled COPD patients had moderate-severe disease. Subjects with a smoking history of ≥20 pack-years and normal lung function (FEV1 > 80% predicted) were defined as smokers. The exclusion criteria were as follows: (i) COPD patients who had experienced any exacerbation less than 3 months prior to inclusion. The study was approved by the local ethics committee of Beijing Tongren Hospital, Capital Medical University (TRECKT2008-14). All subjects provided informed consent to join the study.
Measurements of BMD
BMD at the lumbar spine (L1-L4) and the bilateral femoral necks was measured by Dual X-Ray Absorptiometry (Lunar prodigy, GE Healthcare, London, UK) in 59 patients with COPD, 32 smokers and 25 normal controls. BMD is reported as an absolute value (g/cm 2 ) and a T score, which represents the number of SDs from a young, gender-specific and ethnic groupspecific reference mean. T scores are used for diagnosis of osteopenia or osteoporosis. Normal BMD: T score > −1 at both sites (femoral neck and lumbar spine); osteopenia: T score ≤−1 but >−2.5 at either site; osteoporosis: T score ≤−2.5 at either site. 15 Accordingly, we classified the subjects into two groups: COPD with normal BMD (n = 29, 49.2%) and COPD with low BMD (osteopenia/osteoporosis) (n = 30, 50.8%). In the 32 smokers with normal lung function and 25 neversmoker controls, there were 5 (15.6%) and 3 (12.0%) subjects with a low BMD, respectively. Because decrease of BMD at the femoral necks appears earlier than the lumbar spine, 16 we used only femoral BMD (average of both sides) for data analysis.
Flow cytometric analysis
Freshly collected anti-coagulated peripheral blood (130 μL) from each subject (59 COPD patients, 32 smokers and 25 normal controls) was stained with 4 μL mouse anti-human CD62L-FITC, RANKL-PE, CD16-Percp and CD11b-APC fluorescent antibodies (all from Becton Dickinson (BD) Pharmingen, San Jose, California, USA) for 15 min at room temperature. The blood was then lysed with FACS lysing solution (BD Pharmingen) and analysed using FACSCalibur and FlowJo software (TreeStar, Ashland, OR, USA). Isotype control antibodies (BD Pharmingen) were used to distinguish positive and negative cells in the FITC, PE, PerCP and APC fluorescence channels.
Plasma cytokine analysis
Cytokine concentrations in plasma samples (26 COPD patients, 24 smokers and 18 normal controls) were measured in duplicates using the quantitative sandwich ELISA following the manufacturer's instructions (MultiSciences (LiankeBio, Hangzhou, China)). The following cytokines were measured: IL-1β (minimum detectable dose is typically <0.15 pg/mL), IL-6 (<0.37 pg/mL), TNF-α (<0.42 pg/mL) and IL-8(<0.78 pg/mL).
Data analysis
Statistical analyses were performed using Instat 3.0 (GraphPad Software Inc, Manhattan, New York, USA). Data are expressed as mean AE SD or as median and IQR (for abnormal distribution parameters). Comparisons of data between two groups were performed by Ttest (for normal distribution parameters) and MannWhitney U-test (for non-normal distribution parameters). For data not distributed normally, comparisons between three groups were made using a one-way Kruskal-Wallis test. Correlation was assessed by calculating Spearman's rank correlation coefficient. Here, significance was set at P-value <0.05.
RESULTS
RANKL-expressing neutrophils in the blood of COPD patients with osteoporosis
The percentage (%) and the absolute number (×10 9 ) of peripheral blood neutrophils are shown in Table 1 . The number of neutrophils was higher in COPD patients than in normal controls and smokers (Table 1) .
We used CD11b antibody and RANKL antibody in flow cytometric analysis to detect the RANKLexpressing (RANKL + ) neutrophils. Our results showed that the percentage of RANKL + neutrophils was increased in COPD patients as compared to normal controls ( Fig. 1 , P < 0.0001) and smokers ( Fig. 1 , P < 0.0001), but there was no difference between normal controls and smokers (Fig. 1) .
We further analysed the difference in RANKL + neutrophils between COPD patients with normal BMD (n = 29)and with low BMD (n = 30). The percentage of RANKL + neutrophils was significantly higher in patients with low BMD (Fig. 1C) . bright CD16 bright CD11b bright subset, and measured RANKL expression on these cells. First, our results showed that the activated neutrophils were increased in COPD patients (n = 18) as compared to healthy controls (n = 17) and smokers (n = 30) (Fig. S1, Supplementary Information) . Second, activated neutrophils, despite their small proportion in the whole population, expressed a much higher level of RANKL as compared to mature neutrophils in all the study groups (Fig. 2) . Finally, the percentage of RANKL-expressing cells in both subsets was significantly higher in COPD patients (Fig. 2) .
Activated neutrophils and RANKL expression in COPD
Correlation between RANKL-expressing neutrophils, femoral BMD and lung function
We further analysed whether there were correlations between the percentage of RANKL-expressing neutrophils with femoral BMD or FEV1. Our results showed that the percentage of RANKL + neutrophils correlated negatively with BMD (Fig. 3A) and FEV1% predicted (Fig. 3B ) in all the subjects (n = 116). The percentage of RANKL + cells in activated neutrophils also correlated with BMD (Fig. 3C ) and FEV1% predicted (Fig. 3D ) in COPD patients, smokers and normal controls combined (n = 65). As expected, femoral BMD correlated with FEV1% predicted in all the subjects (n = 116) (Fig. S2, Supplementary Information) .
Association between plasma levels of IL-1β, IL-6 and IL-8 in COPD and RANKL expression
Previous studies have shown that IL-1β, IL-6, TNF-α and IL-8 were able to promote RANKL expression by fibroblasts and T lymphocytes via STAT3 pathway. [17] [18] [19] As systemic inflammation is a feature of COPD, 20 we speculated that upregulated pro-inflammatory cytokines in the systemic circulation of COPD patients might be related to the enhanced RANKL expression by 
Neutrophils in COPD with osteoporosis
neutrophils. Therefore, we measured the plasma level of the above-mentioned cytokines in COPD patients (n = 26), smokers (n = 24) and normal controls (n = 18). Our results showed that IL-1β, IL-6, TNF-α and IL-8 were increased in COPD patients as compared to healthy controls (Fig. S3 , Supplementary Information). Correlation analysis showed that IL-1B (Fig. 4A ), IL-6 (Fig. 4B) , and IL-8 ( Fig. 4C ), but not TNF-α (data not shown), were associated with the percentage of RANKL-expressing neutrophils in all the three groups combined.
DISCUSSION
This study showed, for the first time to our knowledge, that RANKL-expressing neutrophils were increased in peripheral blood from male patients with stable COPD as compared to smokers with normal lung function and healthy non-smokers of the same gender. More importantly, the percentage of RANKL + neutrophils was higher in COPD patients with osteoporosis/ osteopenia as compared to those with normal BMD, and correlated inversely with BMD. We further demonstrated that in these well-defined patients with stable COPD, activated neutrophils were increased in the blood and had enhanced expression of RANKL as compared to non-activated mature neutrophils. RANKL expression by activated neutrophils was also correlated with BMD and FEV1% predicted, and therefore revealing a potential mechanism linking lung destruction and osteoporosis in this complex disease.
Cigarette smoke-induced inflammation is central to the pathogenesis of COPD. Abnormal and persistent inflammation occurs locally and systemically, which leads to progressive decline of lung function. 7, 21 In COPD, this chronic inflammation is predominantly neutrophilic, and neutrophils also mediate the systemic effects of the disease. 11, 22 Aberrant neutrophil infiltration and function in the airways and lung tissues have been confirmed by many studies, but the behaviour and the exact roles of peripheral blood neutrophils in systemic inflammation, especially in extrapulmonary manifestations and co- morbidities, are less clear. One study found that circulating neutrophils from patients with COPD were primed for enhanced responsiveness (degranulation and oxidative burst), and this priming was most notable during exacerbations, perhaps due to exposure to circulating cytokines. 23 Neutrophil priming (preactivation) can promote its destructive effect. Another study, by using gene profiling, analysed the peripheral neutrophils from patients with stable COPD, and found that these neutrophils were in activated state and correlated with disease severity. 24 They also found that cytokines and mediators such as TNF-α might induce the activation of neutrophils in COPD, and in severe COPD, there was an imbalance between pro-inflammatory and anti-inflammatory mediators in neutrophils, and the imbalance towards pro-inflammatory response might participate in the systemic inflammation of COPD. 24 Yamagata et al. revealed that in patients with stable COPD, both CD-11b and CXCR1 expressions in circulating neutrophils were significantly increased and correlated inversely with the severity of airflow limitation, suggesting that overexpression of CD-11b and CXCR1 in circulating neutrophils may be associated with the development of airflow limitation in COPD. 25 More recently, Andelid et al. provided evidence for systemic neutrophil mobilization in patients with clinically stable COPD. 26 Systemic biomarkers of neutrophilic inflammation were also found closely related to disease severity of COPD in another study. 27 Given the above-mentioned evidence for activation of peripheral neutrophils in COPD, the potential effect of neutrophils in systemic diseases of COPD has been scarcely reported. A recent study of Menon et al. provided direct evidence for the important role of circulating neutrophils in extrapulmonary manifestations of COPD, 28 by demonstrating that there was significant neutrophil infiltration in quadriceps muscle biopsies from COPD patients, and the number of neutrophils increased significantly after resistance exercise.
Our results were consistent with the abovementioned studies in that activated neutrophils were increased in the blood from patients with stable COPD. Our finding that RANKL-expressing neutrophils were correlated with BMD suggests that these cells are likely involved in the development and progression of bone destruction in COPD. It can be inferred from the findings of Menon et al. that these RANKL + neutrophils infiltrate the bone tissue and promote osteoclastogenesis by cell-cell contact with preosteoclasts, 28 a mechanism demonstrated by Chakravarti et al., 11 although it is technically difficult to reveal the direct contact of RANKL + neutrophils with preosteoclasts in COPD patients.
Previous studies have shown that proinflammatory cytokines such as IL-1β, IL-6, TNF-α and IL-8 are capable of inducing the expression of RANKL by neutrophils. 17, 29, 30 We found that the plasma levels of these cytokines were increased, and correlated with the frequency of RANKL + neutrophils in COPD patients, suggesting that systemic inflammatory milieu is likely the driving mechanism for RANKL expression by neutrophils in COPD. Because cigarette smoking is associated with bone loss, it is interesting for future studies to explore whether smoking per se has any effect on RANKL expression by neutrophils.
There are several limitations to our study. We only revealed increased frequency of RANKL-expressing neutrophils in male patients with COPD, but the osteoclastogenic function of these cells was not confirmed. There is still a lack of direct evidence for the mechanisms underlying enhanced expression of RANKL by neutrophils, particularly how tobacco smoke impacts RANKL expression. Finally, we did not measure the blood levels of soluble RANKL and OPG to explore their relationship with mRANKL, as our previous study had shown disturbance of the OPG/RANKL pathway in COPD. 10 Further studies are needed to elucidate the complex interactions between soluble and mRANKL and their contribution to bone loss in COPD.
In conclusion, peripheral neutrophils express a higher level of mRANKL in COPD male patients with osteoporosis/osteopenia. The association of RANKLexpressing neutrophils with BMD and lung function in COPD suggests that these cells are likely to play important roles in the pathogenesis of osteoporosis. These results provide evidence to support further studies examining the mechanistic links between lung disease and systemic co-morbidities of COPD.
